☆ 4.7 Article

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure

FRONTIERS IN PHARMACOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma

Grace L. Su et al.

Summary: This article presents the research and recommendations for systemic therapies for HCC, providing evidence-based guidelines for patients.

GASTROENTEROLOGY (2022)

Add to Collection

Article Oncology

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience

Wen-Chi Wu et al.

Summary: This study investigated the efficacy and toxicity of lenvatinib combined with nivolumab in advanced HCC patients. The combination therapy showed higher objective response rate, longer progression-free survival, and overall survival compared to lenvatinib alone. Patients with HBV infection and those who met the REFLECT criteria had a better prognosis.

INVESTIGATIONAL NEW DRUGS (2022)

Add to Collection

Article Oncology

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

Qi Li et al.

Summary: First-line lenvatinib plus camrelizumab combination therapy showed better effectiveness than lenvatinib monotherapy in patients with unresectable HCC.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Correction Multidisciplinary Sciences

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study (vol 8, e09538, 2022)

Lei Zhao et al.

HELIYON (2022)

Add to Collection

Article Oncology

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II Trial

Jianming Xu et al.

Summary: Camrelizumab combined with apatinib showed promising efficacy and manageable safety in patients with advanced hepatocellular carcinoma, representing a novel treatment option for these patients.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Medicine, Research & Experimental

Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison

Jorg Trojan et al.

Summary: This study compared the efficacy and safety of cabozantinib and ramucirumab in patients with HCC, finding that cabozantinib significantly prolonged PFS compared to ramucirumab, but the rates of TRAE-related discontinuations were similar between the two treatments.

ADVANCES IN THERAPY (2021)

Add to Collection

Correction Oncology

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (vol 11, 737767, 2021)

Yuan-Hung Kuo et al.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis

Andrea Casadei-Gardini et al.

Summary: The study found no difference in overall survival between regorafenib and cabozantinib in HCC patients previously treated with sorafenib, but a greater benefit may be expected from cabozantinib treatment in faster progressing patients on prior sorafenib therapy.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Shukui Qin et al.

Summary: This study demonstrates that apatinib significantly improved overall survival in patients with pretreated advanced hepatocellular carcinoma compared with placebo, with a manageable safety profile.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma

M. Ducreux et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma

Laura Torrens et al.

Summary: The combination treatment of lenvatinib and anti-PD1 showed tumor regression and faster response time in mouse HCC models. It significantly inhibited immune suppressive signaling and induced an immune-active microenvironment. Based on immune-related genomic profiles in human HCC, 22% of patients were identified as potential responders.

HEPATOLOGY (2021)

Add to Collection

Article Oncology

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Robin Kate Kelley et al.

Summary: This study evaluated the treatment regimens for patients with hepatocellular carcinoma and found that all regimens were tolerable and clinically active, with the T300 + D regimen showing the most favorable benefit-risk profile. Early expansion of CD8+ lymphocytes was associated with treatment response across arms.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+CD25+Foxp3+regulatory T cells in the immune microenvironment

Alessandro Granito et al.

Summary: Over 90% of hepatocellular carcinoma cases occur in patients with cirrhosis, with hepatitis B virus and hepatitis C virus as leading causes. Immunotherapy has revolutionized HCC treatment by targeting immune cells rather than cancer cells, particularly focusing on regulatory T cells for their role in tumor progression and response to immune checkpoint inhibitors.

WORLD JOURNAL OF GASTROENTEROLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Experience with regorafenib in the treatment of hepatocellular carcinoma

Alessandro Granito et al.

Summary: Regorafenib, structurally similar to sorafenib, shows significant survival advantage in unresectable hepatocellular carcinoma (HCC) patients who failed first-line treatment, by targeting angiogenic and tumor growth-promoting pathways, inhibiting tumor neo-angiogenesis and proliferation, and modulating the tumor microenvironment. It is being explored for use in combination therapy with immune checkpoint blockade and for extended use in patient categories beyond registrative studies.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)

Add to Collection

Article Oncology

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

Robin Kate Kelley et al.

ESMO OPEN (2020)

Add to Collection

Article Gastroenterology & Hepatology

Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma

Won-Mook Choi et al.

HEPATOLOGY COMMUNICATIONS (2020)

Add to Collection

Review Oncology

The Role of Angiogenesis in Hepatocellular Carcinoma

Michael A. Morse et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Oncology

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero et al.

HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Richard S. Finn et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

Add to Collection

Article Oncology

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

Dal Fukurnura et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

G. K. Abou-Alfa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Multidisciplinary Sciences

Role of PD-1 during effector CD8 T cell differentiation

Eunseon Ahn et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)

Add to Collection

Review Oncology

Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

Jiang Chen et al.

CANCER LETTERS (2015)

Add to Collection

Article Gastroenterology & Hepatology

Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion

Martin Franz Sprinzl et al.

JOURNAL OF HEPATOLOGY (2015)

Add to Collection

Review Gastroenterology & Hepatology

Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma

Hashem B. El-Serag

GASTROENTEROLOGY (2012)

Add to Collection

Article Oncology

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann-Lii Cheng et al.

LANCET ONCOLOGY (2009)

Add to Collection

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Review Gastroenterology & Hepatology

Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis

Hashem B. El-Serag et al.

GASTROENTEROLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.